Expertise in
3
conditions

Dr. Jeffrey R. Infante

Oncology
250 25th Ave N, Ste 100, 
Nashville, TN 
Accepting New Patients
Expertise in
3
conditions
250 25th Ave N, Ste 100, 
Nashville, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jeffrey Infante is an Oncologist in Nashville, Tennessee. Dr. Infante is highly rated in 3 conditions, according to our data. His top areas of expertise are Melanoma, Agranulocytosis, Metastatic Uveal Melanoma, and Rectocele. Dr. Infante is currently accepting new patients.

His clinical research consists of co-authoring 162 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in MD
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO

Locations

250 25th Ave N, Ste 100, Nashville, TN 37203

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors
A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 15, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
Enrollment Status: Withdrawn
Publish Date: July 24, 2024
Intervention Type: Drug
Study Drugs: IMCgp100, Durvalumab, Tremelimumab
Study Phase: Phase 1/Phase 2
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
Enrollment Status: Active_not_recruiting
Publish Date: April 05, 2024
Intervention Type: Drug
Study Drug: PT-112
Study Phase: Phase 2
Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies
Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: August 03, 2022
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors
Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: July 20, 2022
Intervention Type: Drug
Study Phase: Phase 1
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1-2 Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
A Phase 1-2 Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: November 02, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: March 20, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Study of PTC596 in Patients With Advanced Solid Tumors
A Phase 1 Study of PTC596 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: December 08, 2017
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Subjects With Metastatic Non-Hematologic Malignancies
A Phase I Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Subjects With Metastatic Non-Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: July 28, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

162 Total Publications

Gastrointestinal transit scintigraphy in the evaluation of rectocele.
Gastrointestinal transit scintigraphy in the evaluation of rectocele.
Journal: Revista espanola de medicina nuclear e imagen molecular
Published: January 07, 2025
Similar Doctors
Expertise in
26
conditions
Dr. Elizabeth J. Davis
Oncology | Hematology
Expertise in
26
conditions
Dr. Elizabeth J. Davis
Oncology | Hematology

Vanderbilt Health Clinicians, LLC

3601 The Vanderbilt Clinic, 
Nashville, TN 
 (1.1 miles away)
615-322-3000
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Elizabeth Davis is an Oncologist and a Hematologist in Nashville, Tennessee. Dr. Davis has been practicing medicine for over 16 years is highly rated in 26 conditions, according to our data. Her top areas of expertise are Adult Soft Tissue Sarcoma, Chondrosarcoma, Angiosarcoma of the Scalp, Angiosarcoma, and Hernia Surgery. Dr. Davis is currently accepting new patients.

Expertise in
11
conditions
Dr. Ingrid A. Mayer
Oncology | Hematology
Expertise in
11
conditions
Dr. Ingrid A. Mayer
Oncology | Hematology
Nashville, TN 
 (1.8 miles away)
615-322-3000
Languages Spoken:
English
See accepted insurances

Ingrid Mayer is an Oncologist and a Hematologist in Nashville, Tennessee. Dr. Mayer is highly rated in 11 conditions, according to our data. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Angiosarcoma, and HER-2 Positive Breast Cancer.

Expertise in
14
conditions
Dr. Jordan D. Berlin
Oncology
Expertise in
14
conditions
Dr. Jordan D. Berlin
Oncology

Vanderbilt Health Clinicians, LLC

3601 The Vanderbilt Clinic, 
Nashville, TN 
 (1.1 miles away)
615-322-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jordan Berlin is an Oncologist in Nashville, Tennessee. Dr. Berlin is highly rated in 14 conditions, according to our data. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Cancer, Colorectal Cancer, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Berlin is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Infante's expertise for a condition
ConditionClose
      View All 35 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile